Democrat-Controlled House Will Turn Up The Volume On Drug Pricing
Executive Summary
With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.
You may also be interested in...
Part D Coverage Gap Discount Relief Misses Ride On Opioids Bill
Biopharma will continue to seek ways to pass legislation reducing the 70% discount in Medicare Part D coverage gap but it looks like industry's next chance will be after the November elections.
DTC Ad Price Disclosure Provision Stripped From US Funding Bill
Even though measure was blocked in Congress, it may still advance through regulation.
Medicare Part D Plans Can Start Negotiating Indication-Based Pricing This Fall
Policy exempts indications covered by protected classes policy, including cancer treatments.